Table 6 Reason(s) for choosing vinflunine for management of a patient following progression/relapse to an initial platinum-based chemotherapy
Reason(s) for choosing vinflunine for management of a patient after progression/relapse to an initial platinum-based chemotherapy, n = 51 physicians (0 up to a maximum of 3 reasons could be given) | |
|---|---|
Phase III evidence | 34 (66.7 %) |
Safety profile | 21 (41.2 %) |
Survival benefit | 15 (29.4 %) |
Drug approval | 13 (25.5 %) |
Guidelines | 12 (23.5 %) |
Progression free survival | 11 (21.6 %) |
Convenience of administration | 9 (17.6 %) |
Good prior experience | 6 (11.8 %) |
Best efficacy expectations | 5 (9.8 %) |
Symptoms control | 4 (7.8 %) |
Quality of life | 3 (5.9 %) |
Simple scheme | 3 (5.9 %) |
Handable schedule | 2 (3.9 %) |
Disease stabilization rate | 1 (2.0 %) |
Patient/family request/other reason | - |